Tissue Reinforcement of Incisional Closure Among High Risk Patients

July 19, 2022 updated by: Julie Holihan, The University of Texas Health Science Center, Houston

Half of all individuals will undergo abdominal surgery in their lifetime. Following abdominal surgery, 30% of patients will suffer a major chronic complication with their wound closure in the first post-operative year. This may include significant wound infections, open wounds, fluid collections, fascial dehiscence, or incisional hernia. These complications not only have a substantial impact on the health care system (cost and chronic disease) and the hospital (cost and space), but most importantly have a substantial impact on the patient. Major chronic wound complications adversely impact patient quality of life and function. Potential methods to reduce major wound complications include utilizing specific suturing techniques or reinforcing the incision line. Suturing technique of small-bites (0.5x0.5 cm bites) as opposed to large bites (1.0x1.0 cm bites) has been shown to be efficacious in European populations with a typical body mass index of 20-25 kg/m2. Tissue reinforcement has been shown to decrease rates of major wound complications in small randomized controlled trials.

However, the lack of widespread adoption of these practices may be due to issues of generalizability including strict inclusion criteria, careful patient selection, and small study size. For example, the generalizability of small bites to an overweight population (mean BMI in the United States is 28 kg/m2) as opposed to a normal-weight population are unclear. The use of synthetic materials in comorbid patients or complex settings may risk major wound complications such as prosthetic infection. Biologic materials have been shown to be effective in decreasing major wound complications but in different settings. This study is being done to assess the effectiveness of different efficacious strategies to decrease the rate of major wound complications following abdominal surgery among high-risk individuals The researchers hypothesize:

  1. Among high-risk patients undergoing abdominal surgery, the use of "small-bites" closure as opposed to "large-bites" closure will increase the proportion of patients who are free of major, chronic wound complications at 1-year post-operative.
  2. Among high-risk patients undergoing abdominal surgery, the biologic tissue reinforcement of the suture line as opposed to no reinforcement will increase the proportion of patients who are free of major, chronic wound complications at 1-year post-operative.

Study Overview

Study Type

Interventional

Enrollment (Actual)

163

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Houston, Texas, United States, 77030
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, United States, 77026
        • Lyndon B. Johnson (LBJ) Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

All high-risk patients undergoing laparotomy or laparoscopic-assisted abdominal surgery. This includes:

  1. all overweight patients (BMI>=25 kg/m2),
  2. current smokers,
  3. those who are immunosuppressed,
  4. those who are malnourished, or
  5. those who are undergoing a contaminated case (CDC wound classification of 2 or 3).

Exclusion Criteria:

  1. patients unlikely to follow-up in a year (e.g. no phone or lives out of state),
  2. patients unlikely to survive more than 2 years based upon surgeon judgment (e.g. metastatic cancer, end-stage cirrhosis),
  3. patients where the clinician would not place prosthetic (e.g. pregnant patient, pediatric patient during growth stage),
  4. patient has a planned second surgery within the next year (e.g. ostomy reversal).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Biologic Mesh and Small Bites
Biologic mesh placement and small bites used for suturing.
Biologic mesh placed during surgery
0.5 cm x 0.5 cm sutures used
Experimental: Small Bites and No Biologic Mesh
Small bites used for suturing with no placement of biologic mesh
0.5 cm x 0.5 cm sutures used
Experimental: Biologic mesh and Large Bites
Biologic mesh placement and large bites used for suturing
Biologic mesh placed during surgery
1.0 x 1.0 sutures used
Active Comparator: Large Bites and no biologic mesh
Large bites used for suturing and no placement of biologic mesh.
1.0 x 1.0 sutures used

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants Major Chronic Wound Infection
Time Frame: 1 year after surgery
Proportion of participants with major chronic wound infection
1 year after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Major Complications
Time Frame: 1 year after surgery
Major complications include surgical site infection, ventral incisional hernia, and/or reoperation
1 year after surgery
Number of Participants With Surgical Site Infections
Time Frame: 1 year after surgery
1 year after surgery
Number of Participants With Reoperations
Time Frame: 1 year after surgery
any unplanned invasive procedure involving the fascia, mesh, or peritoneal cavity
1 year after surgery
Operative Duration
Time Frame: about 119 minutes to 337 minutes
length of the entire procedure
about 119 minutes to 337 minutes
Participants Quality of Life as Assessed by Activities Assessment Scale
Time Frame: 1 year after surgery
Quality of life is scored from 1 to 100, where the higher the score the higher quality of life
1 year after surgery
Participants Health Status as Assessed by the Euroqol-5D Questionnaire
Time Frame: 1 year after surgery
Health Status is scored from 0 to 100, where the higher the score the better the health
1 year after surgery
Cost Analyses
Time Frame: 1 year after surgery
calculated from the hospital's perspective by assessing charges for all patient visits, admissions, and procedures
1 year after surgery
Surgeon Perception
Time Frame: 1 year after surgery
likert type and open ended questions assessing perception, barriers and likelihood of utilizing interventions outside of the trial
1 year after surgery
Number of Participants With Major Complications
Time Frame: 3 years after surgery
Major complications include surgical site infection, ventral incisional hernia, and/or reoperation
3 years after surgery
Number of Participants With Surgical Site Infections
Time Frame: 3 years after surgery
3 years after surgery
Number of Participants With Reoperations
Time Frame: 3 years after surgery
any unplanned invasive procedure involving the fascia, mesh, or peritoneal cavity
3 years after surgery
Participants Quality of Life as Assessed by Activities Assessment Scale
Time Frame: 3 years after surgery
Quality of life is scored from 1 to 100, where the higher the score the higher quality of life
3 years after surgery
Participants Health Status as Assessed by the Euroqol-5D Questionnaire
Time Frame: 3 years after surgery
Health Status is scored from 0 to 100, where the higher the score the better the health
3 years after surgery
Cost Analyses
Time Frame: 3 years after surgery
calculated from the hospital's perspective by assessing charges for all patient visits, admissions, and procedures
3 years after surgery
Surgeon Perception
Time Frame: 3 years after surgery
likert type and open ended questions assessing perception, barriers and likelihood of utilizing interventions outside of the trial
3 years after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Julie Holihan, MD, The University of Texas Health Science Center, Houston

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 13, 2017

Primary Completion (Actual)

June 19, 2021

Study Completion (Actual)

June 19, 2021

Study Registration Dates

First Submitted

May 5, 2017

First Submitted That Met QC Criteria

May 8, 2017

First Posted (Actual)

May 11, 2017

Study Record Updates

Last Update Posted (Actual)

July 22, 2022

Last Update Submitted That Met QC Criteria

July 19, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • HSC-MS-17-0063

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wound Complication

Clinical Trials on Biologic Mesh

3
Subscribe